ADAR1: A New Target for Immuno-oncology Therapy.

Bhate, Amruta; Sun, Tao; Li, Jin Billy

Bhate, Amruta; Sun, Tao; Li, Jin Billy.

Affiliation

Bhate A; Stanford University Department of Genetics, Stanford, CA 94305, USA.
Sun T; Stanford University Department of Genetics, Stanford, CA 94305, USA.
Li JB; Stanford University Department of Genetics, Stanford, CA 94305, USA. Electronic address: jin.billy.li@stanford.edu.

Mol Cell ; 73(5): 866-868, 2019 03 07.

Article in En | MEDLINE | ID: mdl-30849393

ABSTRACT

Three recent studies by Ishizuka et al. (2019), Liu et al. (2019), and Gannon et al. (2018) show that deleting RNA editing enzyme ADAR1 could induce higher cell lethality and render tumor cells more vulnerable to immunotherapy, pinpointing ADAR1 as a new immuno-oncology target.

Subject(s)

Adenosine Deaminase/metabolism; Genetic Therapy/methods; Immunotherapy/methods; Neoplasms/therapy; RNA, Double-Stranded/metabolism; RNA-Binding Proteins/metabolism; Adenosine Deaminase/genetics; Adenosine Deaminase/immunology; Animals; CRISPR-Cas Systems; Cell Survival; Gene Editing; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Immunity, Innate; Interferon-Induced Helicase, IFIH1/genetics; Interferon-Induced Helicase, IFIH1/metabolism; Neoplasms/enzymology; Neoplasms/genetics; Neoplasms/immunology; RNA Editing; RNA, Double-Stranded/genetics; RNA, Double-Stranded/immunology; RNA-Binding Proteins/genetics; RNA-Binding Proteins/immunology

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: RNA, Double-Stranded / Genetic Therapy / Adenosine Deaminase / RNA-Binding Proteins / Immunotherapy / Neoplasms Limits: Animals / Humans Language: En Journal: Mol Cell Journal subject: BIOLOGIA MOLECULAR Year: 2019 Document type: Article Affiliation country: United States Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google